U.S. pharmaceutical companies can now be sued for forging deals to keep the cost of drugs high to delay the creation of generic and less expensive drugs. These deals are known as 'pay-to-delay' arrangments and the Supreme Court ruled them "presumptively unlawful", though they did not go so far as to call the practice illegal. Justices said litigants could still challenge deals individually on a case-by-case basis. Read the full story.